The COVID-19 pandemic has prompted pharmaceutical companies across the world to develop contingency plans to tackle potential disruptions.
GlobalData has conducted a survey to determine if companies across North America, Asia Pacific (APAC), Europe and Rest of World (ROW) have developed scenarios to respond to coronavirus-related disruptions.
An analysis of the survey responses has revealed that planning for COVID-19 related disruptions was highest in North America in Q3 at 91%, compared to 78% in Q1, as companies began to develop contingency plans.
In Europe, the percentage of companies that had developed planning scenarios increased from 63% in Q1 to 71% in Q3.
The survey, further, found that 56% of the respondents from APAC had planned for disruptions related to COVID-19 in Q1, which increased to 67% in Q3. For companies in ROW, however, the figure dropped from 70% in Q1 to 60% in Q3.
The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey conducted between 07 July and 30 July 2020.
